These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
245 related articles for article (PubMed ID: 31312965)
1. Rational Design, synthesis and biological evaluation of novel triazole derivatives as potent and selective PRMT5 inhibitors with antitumor activity. Zhu K; Shao J; Tao H; Yan X; Luo C; Zhang H; Duan W J Comput Aided Mol Des; 2019 Aug; 33(8):775-785. PubMed ID: 31312965 [TBL] [Abstract][Full Text] [Related]
2. Discovery of Novel PRMT5 Inhibitors by Virtual Screening and Biological Evaluations. Tao H; Yan X; Zhu K; Zhang H Chem Pharm Bull (Tokyo); 2019; 67(4):382-388. PubMed ID: 30930442 [TBL] [Abstract][Full Text] [Related]
3. Discovery of new potent protein arginine methyltransferase 5 (PRMT5) inhibitors by assembly of key pharmacophores from known inhibitors. Zhu K; Song JL; Tao HR; Cheng ZQ; Jiang CS; Zhang H Bioorg Med Chem Lett; 2018 Dec; 28(23-24):3693-3699. PubMed ID: 30366617 [TBL] [Abstract][Full Text] [Related]
4. Discovery and optimization of selective inhibitors of protein arginine methyltransferase 5 by docking-based virtual screening. Ye Y; Zhang B; Mao R; Zhang C; Wang Y; Xing J; Liu YC; Luo X; Ding H; Yang Y; Zhou B; Jiang H; Chen K; Luo C; Zheng M Org Biomol Chem; 2017 May; 15(17):3648-3661. PubMed ID: 28397890 [TBL] [Abstract][Full Text] [Related]
5. Potent, Selective, and Cell Active Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor Developed by Structure-Based Virtual Screening and Hit Optimization. Mao R; Shao J; Zhu K; Zhang Y; Ding H; Zhang C; Shi Z; Jiang H; Sun D; Duan W; Luo C J Med Chem; 2017 Jul; 60(14):6289-6304. PubMed ID: 28650658 [TBL] [Abstract][Full Text] [Related]
6. Identification of a novel selective small-molecule inhibitor of protein arginine methyltransferase 5 (PRMT5) by virtual screening, resynthesis and biological evaluations. Zhu K; Jiang C; Tao H; Liu J; Zhang H; Luo C Bioorg Med Chem Lett; 2018 May; 28(9):1476-1483. PubMed ID: 29628326 [TBL] [Abstract][Full Text] [Related]
7. Discovery of selective protein arginine methyltransferase 5 inhibitors and biological evaluations. Ji S; Ma S; Wang WJ; Huang SZ; Wang TQ; Xiang R; Hu YG; Chen Q; Li LL; Yang SY Chem Biol Drug Des; 2017 Apr; 89(4):585-598. PubMed ID: 27714957 [TBL] [Abstract][Full Text] [Related]
8. A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models. Chan-Penebre E; Kuplast KG; Majer CR; Boriack-Sjodin PA; Wigle TJ; Johnston LD; Rioux N; Munchhof MJ; Jin L; Jacques SL; West KA; Lingaraj T; Stickland K; Ribich SA; Raimondi A; Scott MP; Waters NJ; Pollock RM; Smith JJ; Barbash O; Pappalardi M; Ho TF; Nurse K; Oza KP; Gallagher KT; Kruger R; Moyer MP; Copeland RA; Chesworth R; Duncan KW Nat Chem Biol; 2015 Jun; 11(6):432-7. PubMed ID: 25915199 [TBL] [Abstract][Full Text] [Related]
9. Identification of 5-benzylidene-2-phenylthiazolones as potent PRMT5 inhibitors by virtual screening, structural optimization and biological evaluations. Zhu K; Tao H; Song JL; Jin L; Zhang Y; Liu J; Chen Z; Jiang CS; Luo C; Zhang H Bioorg Chem; 2018 Dec; 81():289-298. PubMed ID: 30172110 [TBL] [Abstract][Full Text] [Related]
10. Discovery of 2-substituted-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-1,2,3,4-tetrahydroisoquinoline-6-carboxamide as potent and selective protein arginine methyltransferases 5 inhibitors: Design, synthesis and biological evaluation. Shao J; Zhu K; Du D; Zhang Y; Tao H; Chen Z; Jiang H; Chen K; Luo C; Duan W Eur J Med Chem; 2019 Feb; 164():317-333. PubMed ID: 30605830 [TBL] [Abstract][Full Text] [Related]
11. Synthesis and Activity of Triazole-Adenosine Analogs as Protein Arginine Methyltransferase 5 Inhibitors. Brown T; Cao M; Zheng YG Molecules; 2022 Jun; 27(12):. PubMed ID: 35744905 [TBL] [Abstract][Full Text] [Related]
12. Discovery of novel PRMT5 inhibitors bearing a methylpiperazinyl moiety. Bai X; Zhai Z; Zhao X; Li R; Liang L; Jin Y; Yin Y Future Med Chem; 2022 Jul; 14(14):1071-1086. PubMed ID: 35748226 [No Abstract] [Full Text] [Related]
13. Myelocytomatosis-Protein Arginine N-Methyltransferase 5 Axis Defines the Tumorigenesis and Immune Response in Hepatocellular Carcinoma. Luo Y; Gao Y; Liu W; Yang Y; Jiang J; Wang Y; Tang W; Yang S; Sun L; Cai J; Guo X; Takahashi S; Krausz KW; Qu A; Chen L; Xie C; Gonzalez FJ Hepatology; 2021 Oct; 74(4):1932-1951. PubMed ID: 33896016 [TBL] [Abstract][Full Text] [Related]
14. The Development of Tetrazole Derivatives as Protein Arginine Methyltransferase I (PRMT I) Inhibitors. Sun Y; Wang Z; Yang H; Zhu X; Wu H; Ma L; Xu F; Hong W; Wang H Int J Mol Sci; 2019 Aug; 20(15):. PubMed ID: 31390828 [TBL] [Abstract][Full Text] [Related]
15. Identification of Selective, Cell Active Inhibitors of Protein Arginine Methyltransferase 5 through Structure-Based Virtual Screening and Biological Assays. Ye F; Zhang W; Ye X; Jin J; Lv Z; Luo C J Chem Inf Model; 2018 May; 58(5):1066-1073. PubMed ID: 29672052 [TBL] [Abstract][Full Text] [Related]
16. Identification of PRMT5 inhibitors with novel scaffold structures through virtual screening and biological evaluations. Zhang Q; Zhang L; Jin J; Fan Y; Wang X; Hu H; Ye X; Wang L; Cao C; Ye F J Mol Model; 2022 Jun; 28(7):184. PubMed ID: 35680707 [TBL] [Abstract][Full Text] [Related]
17. Arginine Methyltransferase 5 (PRMT5) Inhibitors with 3-(1H-benzo[d]imidazol- 2-yl)anilines Core Identified by Virtual Screening and Biological Evaluation. Zhang Y; Zhu K; Zhang J; Zhang JH; Song Z; Zhang X; Liu SK; Jiang CS Curr Pharm Des; 2023; 29(6):474-479. PubMed ID: 36790004 [TBL] [Abstract][Full Text] [Related]
18. PRMT1 loss sensitizes cells to PRMT5 inhibition. Gao G; Zhang L; Villarreal OD; He W; Su D; Bedford E; Moh P; Shen J; Shi X; Bedford MT; Xu H Nucleic Acids Res; 2019 Jun; 47(10):5038-5048. PubMed ID: 30916320 [TBL] [Abstract][Full Text] [Related]
19. Medicinal chemistry strategies targeting PRMT5 for cancer therapy. Fu S; Zheng Q; Zhang D; Lin C; Ouyang L; Zhang J; Chen L Eur J Med Chem; 2022 Dec; 244():114842. PubMed ID: 36274274 [TBL] [Abstract][Full Text] [Related]
20. Discovery and Pharmacological Characterization of JNJ-64619178, a Novel Small-Molecule Inhibitor of PRMT5 with Potent Antitumor Activity. Brehmer D; Beke L; Wu T; Millar HJ; Moy C; Sun W; Mannens G; Pande V; Boeckx A; van Heerde E; Nys T; Gustin EM; Verbist B; Zhou L; Fan Y; Bhargava V; Safabakhsh P; Vinken P; Verhulst T; Gilbert A; Rai S; Graubert TA; Pastore F; Fiore D; Gu J; Johnson A; Philippar U; Morschhäuser B; Walker D; De Lange D; Keersmaekers V; Viellevoye M; Diels G; Schepens W; Thuring JW; Meerpoel L; Packman K; Lorenzi MV; Laquerre S Mol Cancer Ther; 2021 Dec; 20(12):2317-2328. PubMed ID: 34583982 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]